CPT code 81212 represents a targeted molecular diagnostic test that detects three specific pathogenic variants in the BRCA1 and BRCA2 genes (185delAG, 5385insC, 6174delT). This focused assay is used in clinical laboratories to identify well-characterized, high-impact alterations associated with hereditary breast and ovarian cancer risk. Nationally, BRCA variant testing informs patient risk assessment, clinical management decisions, and access to genetic counseling and targeted therapies, making accurate coding and coverage determinations important for clinicians, laboratories, and payers.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. The publication provides readers with a concise overview of CPT code 81212, expected service characteristics, and the clinical context for targeted BRCA1/BRCA2 variant testing. Readers will find benchmarks for utilization and coverage frameworks, summaries of relevant policy considerations for laboratory reimbursement, and clinical context that explains when targeted variant assays are used versus broader sequencing approaches. Data limitations and missing fields are noted where input information was not provided.